Elite in Cholangitis

Dr. Raj Vuppalanchi

Gastroenterology
University Medical Diagnostic Associates Inc
1701 N Senate Blvd, 
Indianapolis, IN 
Offers Telehealth
21 Years of Experience
Elite in Cholangitis
University Medical Diagnostic Associates Inc
1701 N Senate Blvd, 
Indianapolis, IN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Raj Vuppalanchi is a Gastroenterologist in Indianapolis, Indiana. Dr. Vuppalanchi has been practicing medicine for over 21 years and is rated as an Elite provider by MediFind in the treatment of Cholangitis. His top areas of expertise are Nonalcoholic Steatohepatitis (NASH), Non-Alcoholic Fatty Liver Disease, Cirrhosis, Liver Transplant, and Gastric Bypass.

His clinical research consists of co-authoring 161 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 14 articles in the study of Cholangitis.

Specialties
Gastroenterology
Licenses
Internal Medicine in IN
Hospital Affiliations
Indiana University Health
Margaret Mary Community Hospital Inc
Iu Health West Hospital
Indiana University Health North Hospital
Indiana University Health Arnett Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

UNIVERSITY MEDICAL DIAGNOSTIC ASSOCIATES INC
1701 N Senate Blvd, Indianapolis, IN 46202
Other Locations
UNIVERSITY MEDICAL DIAGNOSTIC ASSOCIATES INC
550 N University Blvd, Indianapolis, IN 46202
UNIVERSITY MEDICAL DIAGNOSTIC ASSOCIATES INC
10300 N Illinois St, Indianapolis, IN 46290

Additional Areas of Focus

Dr. Vuppalanchi has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Enrollment Status: Active_not_recruiting
Publish Date: April 11, 2025
Intervention Type: Drug
Study Drug: Belapectin
Study Phase: Phase 2/Phase 3
Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis
Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2025
Intervention Type: Other
Study Phase: Not Applicable
A Prospective, Randomized, Double-Blind, Sham-Controlled, Multi-Center, Pivotal Study to Evaluate the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects With Type 2 Diabetes With Inadequate Glycemic Control
A Prospective, Randomized, Double-Blind, Sham-Controlled, Multi-Center, Pivotal Study to Evaluate the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects With Type 2 Diabetes With Inadequate Glycemic Control
Enrollment Status: Suspended
Publish Date: February 05, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 2
A Placebo-Controlled, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency (AATD) [SEQUOIA]
A Placebo-Controlled, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency (AATD) [SEQUOIA]
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Other, Drug
Study Drug: ARO-AAT
Study Phase: Phase 2
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
Evaluation of Pharmacokinetics and Safety of Saroglitazar Magnesium in Participants with Normal Hepatic Function and with Hepatic Impairment, Cholestatic Liver Disease, NASH with Advanced Fibrosis
Evaluation of Pharmacokinetics and Safety of Saroglitazar Magnesium in Participants with Normal Hepatic Function and with Hepatic Impairment, Cholestatic Liver Disease, NASH with Advanced Fibrosis
Enrollment Status: Completed
Publish Date: September 20, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS )
A Phase 2, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS )
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
Enrollment Status: Terminated
Publish Date: March 09, 2023
Intervention Type: Drug
Study Drug: Obeticholic Acid 
Study Phase: Phase 4
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
Enrollment Status: Completed
Publish Date: September 16, 2020
Intervention Type: Drug
Study Phase: Phase 2
Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants
Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants
Enrollment Status: Completed
Publish Date: November 14, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 10 Less Clinical Trials

161 Total Publications

Future Treatment Options for Managing Primary Sclerosing Cholangitis and Cholestatic Pruritus.
Future Treatment Options for Managing Primary Sclerosing Cholangitis and Cholestatic Pruritus.
Journal: Clinics in liver disease
Published: October 18, 2025
Similar Doctors
Elite in Cholangitis
Dr. Craig Lammert
Gastroenterology
Elite in Cholangitis
Dr. Craig Lammert
Gastroenterology

Iu Health Medical Group LLC

1701 N Senate Blvd, 
Indianapolis, IN 
 (0.1 miles away)
888-484-3258
Languages Spoken:
English
See accepted insurances

Craig Lammert is a Gastroenterologist in Indianapolis, Indiana. Dr. Lammert is rated as an Elite provider by MediFind in the treatment of Cholangitis. His top areas of expertise are Autoimmune Hepatitis, Hepatitis, Cholangitis, Liver Transplant, and Endoscopy.

Elite in Cholangitis
Dr. Mark Gromski
Gastroenterology
Elite in Cholangitis
Dr. Mark Gromski
Gastroenterology

Iu Health Medical Group LLC

1701 N Senate Blvd, 
Indianapolis, IN 
 (0.1 miles away)
888-484-3258
Languages Spoken:
English
See accepted insurances

Mark Gromski is a Gastroenterologist in Indianapolis, Indiana. Dr. Gromski is rated as a Distinguished provider by MediFind in the treatment of Cholangitis. His top areas of expertise are Hereditary Pancreatitis, Cholangitis, Sclerosing Cholangitis, Endoscopy, and Lithotripsy.

Distinguished in Cholangitis
Dr. Evan Fogel
Gastroenterology
Distinguished in Cholangitis
Dr. Evan Fogel
Gastroenterology

Iu Health Medical Group LLC

1701 N Senate Blvd, 
Indianapolis, IN 
 (0.1 miles away)
888-484-3258
Languages Spoken:
English
See accepted insurances

Evan Fogel is a Gastroenterologist in Indianapolis, Indiana. Dr. Fogel is rated as an Elite provider by MediFind in the treatment of Cholangitis. His top areas of expertise are Hereditary Pancreatitis, Chronic Pancreatitis, Sphincter of Oddi Dysfunction, Endoscopy, and Lithotripsy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vuppalanchi's expertise for a condition
ConditionClose
View All 9 Elite Conditions
View All 11 Distinguished Conditions
View All 17 Advanced Conditions
View All 48 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile